Hematopoietic Stem Cell Transplantation in the Department of Hematology, Fukushima Medical University

Ogawa, Kaoru; Noji, Hideyoshi; Furukawa, Miki; Harada-Shirado, Kayo; Mashimo, Yumiko; Takahashi, Hiroshi; Matsumoto, Hayato; Kimura, Satoshi; Shichishima-Nakamura, Akiko; Ohkawara, Hiroshi; Ikeda, Kazuhiko; Ohto, Hitoshi; Takeishi, Yasuchika

doi:10.5387/fms.56.107

Cited by 3 publications

(1 citation statement)

References 8 publications

(7 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…congenital immunodeficiency disease, inherited metabolic disorder). 9,10,11 HSCs for transplantation can be collected from bone marrow or peripheral blood. Instead of bone marrow aspiration and biopsy which are invasive procedures, peripheral blood is a feasible and easily available source now-a-days.…”

Section: Discussionmentioning

confidence: 99%

Haematopoietic Stem Cell Transplantation: A Single Center Experience of Four Years in Bangladesh

Mahfuz¹,

Uddin²,

Karim³

et al. 2022

J. Bangladesh Coll. Phys.

View full text Add to dashboard Cite

Background: Haematopoietic stem cell transplantation (HSCT) is the standard consolidation therapy for a variety of malignant and non-malignant diseases in children and adults. Our experience of HSCT in 26 patients with various indications is shared in this article. Materials and methods: This was a retrospective analysis of first 26 patients who had undergone autologous and allogeneic transplant at our center, with M:F=2.7:1. The mean age for autologous transplant was 45 years (range 23-57 years). The median follow-up period was 23 months 25 days (range 3to 47 months).The data was obtained carefully from medical records of the BMT center. Indications for autologous HSCT were Multiple Myeloma (12 patients), Non- Hodgkin’s lymphoma (7 patients), Hodgkin’s lymphoma (4 patients). Allogeneic HSCT were for Acute Myeloid Leukaemia (3 patients). Results: The mean time for WBC engraftment was 12 days (range: 9-19 days) and for platelet engraftment was 16 days (range: 11-35 days) in our autologous transplant cases and for allogeneic transplant mean time for WBC engraftment was12 days (range: 11-15 days) and for platelet engraftment was 14 days (range: 12-17 days). Irradiated blood components were given in the pre, peri and post-transplant period to maintain Hb>8 gm/dl and platelet count >20X109/L. Mean single-donor platelet requirement was 4 units (range 1-7), and mean packed red cell requirement was 1.5 units (range 1-6). The post-transplant complications encountered were mucositis, infections and diarrhoea. Oral mucositis was the most common complications. Twenty three (88.46 %) out of our 26 HSCT patients had developed mucositis , among them grade 1 in 5 patients, grade 2 in 11 patients, and grade 3 in 7 patients. There were 21(80.76%) cases of febrile neutropenia. Out of 26 patients 13 (50.0%) bacterial infection were documented with culture positivity. One (3.84%) case of viral infection was documented. Major bacterial infections were culture positive with Pseudomonas, Escherichia coli and Klebsiella followed by other species like acinatobacter, burkholderia and coagulase negative staphylococcus. One case of Cytomegalovirus was noted with significant viral copies that required Ganciclovir. Average duration of hospital stay after autologous HSCT was 23 days (range of 14-54 days) and allogeneic HSCT was 35 days (range of 30-57 days). 19 out of our 23 autologous transplant patients were in complete remission and all 03 cases of allogeneic HSCT were in remission. Conclusion: We believe our center has made a remarkable progress within short period of time to develop both autologous and allogeneic HSCT and is comparable with nationally and internationally renowned HSCT centers in terms of standard, quality and safety of care, and the ultimate outcomes. J Bangladesh Coll Phys Surg 2022; 40: 146-152

show abstract

Section: Discussionmentioning

confidence: 99%

Haematopoietic Stem Cell Transplantation: A Single Center Experience of Four Years in Bangladesh

Mahfuz¹,

Uddin²,

Karim³

et al. 2022

J. Bangladesh Coll. Phys.

View full text Add to dashboard Cite

show abstract

Outcome of Patients Treated with Hematopoietic Stem Cell Transplantation: Results from A Single Center

Bahoush

2021

Asia-Pacific Journal of Oncology Nursing

View full text Add to dashboard Cite

Objective: Hematopoietic stem cell transplantation (HSCT) is known as one of the most advanced and modern treatments in the world for various diseases which do not respond well to other therapies. Evaluating outcomes of these patients, especially in newly developed centers, can crucially help in developing and improving the quality of these centers. Methods: In a retrospective analytical cohort study, we statistically analyzed all patients treated with HSCT in the Bone Marrow Transplant Unit of the Ali-Asghar Pediatric Hospital affiliated to Iran University of Medical Sciences. The demographic information as well as all information concerning each patient's transplant process was extracted and statistically analyzed using SPSS Version 23. Results: The mean neutrophilic and platelet engraftment days were, respectively, 16 (range = 12–21) and 22 (range = 15–34) days after HSCT, while the neutrophilic engraftment occurred significantly earlier in allogeneic transplants compared to the autologous ones ( P = 0.020). The total event-free survival (EFS) rate of the patients based on the median follow-up of 12 months was 11.50% ± 53.60%. Based on the total follow-up period, the estimated total EFS rate of the patients was calculated as 35.20% ± 13.50%. The estimated EFS rate was found to be better in patients who had undergone allogeneic transplantation than those who received an autologous transplant ( P = 0.780). Conclusions: The HSCT results at our center are comparable to those at other centers in Iran. We argue that the facility can provide adequate therapy to patients requiring HSCT, on the proviso that some organizational limitations are addressed.

show abstract

Twenty Years of Experience on Stem Cell Transplantation in Iran

Ghavamzadeh¹,

Ghaffari²,

Derakhshandeh³

et al. 2013

Iran Red Crescent Med J

View full text Add to dashboard Cite

BackgroundHematopoietic stem cell transplantation (HSCT) is a new window to therapy of many diseases. From March 1991 through April 2011, a total of 3237 HSCT were performed in the Hematology-Oncology and Stem Cell Transplantation Research Center, affiliated to Tehran University of Medical Sciences. Here we report 20 years experience of HSCT.ObjectivesOur strategy and aim include the protraction of cytogenetic and molecular biological diagnostic tests, the expansion of the first Iranian Cord Blood Bank (ICBB) and development of the first Iranian Stem Cell Donor Program (ISCDP), and improvement the researches in new therapeutic fields.Patients and MethodsTotally, 3237 patients were undergone HSCT. Of these transplants, 2205 were allogeneic stem cell transplantation, 1016 autologous and 16 syngeneic. Among 2205 patients who were undergone allogenic-HSCT, 34 received cord blood stem cells as stem cell source for transplantation. It is important to point out that cord blood bank at our center provides reliable storage of cord blood stem cells for our patients. Stem cell transplantation was performed for treatment of various diseases such as acute myelogenous leukemia, acute lymphoblastic leukemia, chronic myelogenous leukemia, chronic lymphoblastic leukemia, beta-thalassemia major, sickle- cell thalassemia, sickle- cell disease, multiple myeloma, myelodysplasia, mucopolysaccharidosis, paroxysmal nocturnal hemoglobinuria, non-Hodgkin’s lymphoma, Hodgkin’s disease, severe aplastic anemia, plasma cell leukemia, Niemann-Pick disease, Fanconi anemia, severe combined immunodeficiency, congenital neutropenia, leukocyte adhesion deficiencies, Chediak-Higashi syndrome, osteopetrosis, histiocytosis X, Hurler syndrome, amyloidosis, systemic sclerosis, breast cancer, Ewing's sarcoma, testicular cancer, germ cell tumors, neuroblastoma, medulloblastoma, renal cell carcinoma, nasopharyngeal carcinoma, ovarian cancer, Wilms’ tumor, rhabdomyosarcoma, pancreatoblastoma, and multiple sclerosis. Also, we had 220 cellular therapies for post-myocardial infarction, multiple sclerosis, cirrhosis, head of femur necrosis, Diabetes Mellitus and GvHD treatment. 45 patients were undergone retransplantation in this center.ResultsAbout 78.2% of the patients (2530 of 3237) remained alive between one to 211 months after stem cell transplantation. Nearly, 21.8% (707) of our patients died after stem cell transplantation. The main causes of death were relapse, infection, hemorrhagic cystitis, graft-versus- host disease and etc.ConclusionsIn Iran, HSCT has been successfully adapted in routine clinical care. Recently, new methods such as double cord blood and haploidentical transplantation have been used to treat many life-threatening diseases.

show abstract

Hematopoietic Stem Cell Transplantation in the Department of Hematology, Fukushima Medical University

Cited by 3 publications

References 8 publications

Haematopoietic Stem Cell Transplantation: A Single Center Experience of Four Years in Bangladesh

Haematopoietic Stem Cell Transplantation: A Single Center Experience of Four Years in Bangladesh

Outcome of Patients Treated with Hematopoietic Stem Cell Transplantation: Results from A Single Center

Twenty Years of Experience on Stem Cell Transplantation in Iran

Contact Info

Product

Resources

About